Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watch this Space: Medtech in the Middle East

This article was originally published in Start Up

Executive Summary

With all the frenzy of investing, partnering, and joint-venturing in emerging markets like China and India, where can medtech investors still get in on the ground floor? The Middle East. While capital for venture firms and their portfolio companies is growing scarcer in the US and Europe, government and private entities operating within the countries of the MENA (Middle East North Africa) region have billions--and in some cases trillions--to invest to further government goals of diversifying local economies beyond oil and real-estate while also improving their health care systems for their growing populations. Now, the former head of direct investment at the Kuwait Investment Authority is establishing a new $150 million investment fund that will focus on life sciences and telecommunications/IT in the region.

You may also be interested in...



SBI, ConforMIS Think and Act Globally in Search for Funds

Small Bone Innovations and ConforMIS drew capital from across the globe for their $144 million and $50 million financings.

China: The Wild, Wild East for Medical Devices

Every medical device company is asking, "How can we take advantage of emerging opportunities in China?" Given the country's economic and population booms--China is home to one fifth the world's population--many analysts expect its medical device market to shortly come into full bloom, enjoying a compound annual growth rate of 15% over the next 10 years from a base of approximately $10 billion in 2007. Fueling this growth are positive improvements in China's business climate, making China a much less risky place to do business. Multinational firms are forming alliances in China to help them reach an untapped 1.3 billion patient population, even as a new breed of venture capital-backed, Western-style Chinese companies begins to grab a home court advantage.

China: The Asian Dragon Lures Foreign Investors

WuXi PharmaTech's spectacular public offering last summer piqued foreign investors' interest. Top tier VC firms are now investing in contract research organizations, manufacturing plays, and start-ups shifting business operations to China.

Topics

Related Companies

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel